HOXB13 G84E Mutation Associated with Risk of Prostate Cancer

Share this content:

the Cancer Therapy Advisor take:

A rare non-conservative substitution (G84E) in the HOXB13 gene was found to be associated with an increased risk for prostate cancer and other malignancies in male patients, according to a study published online in the journal Cancer Epidemiology, Biomarkers & Prevention.

Participants included 9,012 male patients in the Mayo Clinic Biobank (MCB).  DNA samples were genotyped to calculate the frequency of the G84E variant and its relationship with malignancies and patients completed questionnaires regarding medical history and family history of cancer.

Out of the 9,012 males, 49 were carriers of the G84E mutation (0.5%) and 31% (n = 2,595) of patients were diagnosed with cancer (51.1% of which were G84E carriers and 30.6% were non-carriers (P=0.004).

The G84E mutation was most frequently found in males with prostate cancer compared to males without cancer (P0.0001).  The authors observed that G84E was more common in patients with bladder cancer and leukemia (P=0.06 and P=0.01, respectively).  Male patients who were G84E mutation carriers were more prone to having a family history of prostate cancer in a first degree relative (36.2%) compared with non-carriers (16.0%, P=0.0003).

The study suggests future research focus on understanding the role of the HOXB13 G84E mutation in malignancies and its novel association with leukemia and bladder cancer.

A summary of sessions related to genetic mutations in metastatic castrate-resistant prostate cancer
Rare non-conservative substitution in HOXB13 gene found to be associated with increased risk for prostate cancer and other malignancies.
:A rare non-conservative substitution (G84E) in the HOXB13 gene has been shown to be associated with risk of prostate cancer.
READ FULL ARTICLE From cebp.aacrjournals.org

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs